A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults

Journal of Infectious Diseases

Volumn 199, Issue 5, 2009, Pages 711-716

  Karron, Ruth A ^a   Callahan, Karen ^a   Luke, Catherine ^b   Thumar, Bhagvanji ^a   McAuliffe, Josephine ^b   Schappell, Elizabeth ^a   Joseph, Tomy ^b   Coelingh, Kathleen ^c   Jin, Hong ^c   Kemble, George ^c   Murphy, Brian R ^b   Subbarao, Kanta ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; EPISTAXIS; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H9N2; MALE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; RHINORRHEA;

ADULT; ANTIBODIES, VIRAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED;

EID: 61849106976     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596558     Document Type: Article

References (15)

1. Chen H, Matsuoka Y, Swayne D, et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003; 21:4430-6.
2. Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3:e360.
3. Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, Subbarao K. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol 2007; 81:10558-66.
4. Stephenson I, Nicholson KG, Gluck R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959-66.
5. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991; 29:1175-82.
6. Clements ML, O'Donnel S, Levine MM, Chanock RM, Murphy BR. Dose response of A/Alaska/6/77 (H3N2) cold adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983; 40:1044.
7. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006; 355: 2186-94.
8. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
9. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006; 43:1135-42.
10. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002; 191:203-8.
11. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002; 15:295-323.
12. Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity 2006; 24:5-9.
13. Murphy BR, Rennels MB, Douglas RG Jr, et al. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun 1980; 29:348-55.
14. McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13.
15. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007; 25:5367-73.